ExploreWatchlistsPricing
  1. JP-listed companies
  2. SanBio Company Limited
  3. Financials
  4. Income before tax

SanBio Company Limited (4592)

Market cap
¥154.3B
P/E ratio
-27.4x
SanBio develops cell therapy drugs to help patients recover brain and nervous system functions lost due to injury or diseases like Parkinson's and Alzheimer's.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndIncome before tax (Million JPY)YoY (%)
Jan 31, 2026-4,292+42.00%
Jan 31, 2025-3,022+6.99%
Jan 31, 2024-2,825-39.88%
Jan 31, 2023-4,699+2.60%
Jan 31, 2022-4,580-29.87%
Jan 31, 2021-6,530+26.89%
Jan 31, 2020-5,147+76.26%
Jan 31, 2019-2,920-26.04%
Jan 31, 2018-3,948+82.25%
Jan 31, 2017-2,166+84.77%
Jan 31, 2016-1,172-152.61%
Jan 31, 20152,229-479.61%
Jan 31, 2014-587

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat